LabCorp (NYSE: LH) has launched the HCV FibroSURE, a non-invasive blood test for assessing liver status in hepatitis C virus (HCV) patients.

Developed by hepatologists at the Pitie-Salpetriere Hospital and BioPredictive in France, HCV FibroSURE is only available in the United States through Burlington-based LabCorp.

HCV FibroSURE, which provides an alternative to liver biopsy, uses a combination of six serum biochemical markers plus age and gender in a patented algorithm to determine the degree of liver fibrosis and the level of ongoing necroinflammatory activity.

LabCorp says the test, which has been clinically available in Europe for the past two years, has been shown in several studies to enable quantitative, reproducible assessment of fibrogenic and necrotic activity in the liver of HCV patients.

“The launch of this important new test once again validates LabCorp’s strategy of creating a world-class national laboratory with the best and broadest array of diagnostic testing services,” said Myla Lai-Goldman, executive vice president and chief scientific officer and medical director at LabCorp. “Our focus on bringing forth innovative new technologies and tests, coupled with our scientific expertise and national scope, helps us broadly deliver vital new tools like BioPredictive’s liver fibrosis assay to U.S. physicians managing HCV patients.”